Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease, and Alzheimer’s disease Read more
Russia Calls for Prevention of ‘Full-Scale World War III’ — Official Warns ‘World Tensions Are White-Hot’ – Economics Bitcoin News Read more